Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A phase 1/2 trial of MDX2001 in biliary tract cancer, cervical cancer, colorectal cancer, endometrial cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.
Overview
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239194 by ModeX Therapeutics, An OPKO Health Company, with 285 participants planned, started 2024-06-12 and due to reach its primary completion in 2028-08. Interventions recorded: MDX2001.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialA Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialFeasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialPhase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Colorectal cancer and the tag pipeline.